

at concl.

130. (New) The method of claim 100, wherein the ligand is an antiprogestosterone.

131. (New) The method of claim 100, wherein said ligand requires conversion to an active form in an end organ.

132. (New) The method of claim 100, wherein said ligand has a side chain which increases or restricts solubility, membrane transfer or target organ accessibility.

133. (New) The method of claim 101, wherein said mutated steroid receptor ligand binding domain is Vitamin D.

134. (New) The method of claim 133, wherein said mutated receptor is up-regulated when bound by the ligand 24,25-dihydroxy-Vitamin D.

REMARKS

Applicant has cancelled claims 1-99 without prejudice and added new claims 100-134. These new claims add no new matter and are fully supported by the application as filed. For example, for claim 100, see pages 4-8 and page 9, lines 21-24, page 11, lines 5-24, page 14, lines 9-19, page 16, lines 7-16, page 17, lines 22-26, Examples 15, 17, and 18; for claim 101, see page 5 lines 16-20; for claim 103, see page 11, lines 7-9, Examples 15, 17, and 18; for claim 104, see Examples 17 and 18; for claim 105, see page 5, lines 5-6, page 7, lines 11-16; for claims 106-110, see pages 5-6, Examples 15, 17, and 18; for claim 111, see page 11, lines 7-9, Example 15; for claim 112, see page 16, lines 30-31; for claim 113, see page 6, lines 27-30, page 7, lines 1-10, page 10, lines 11-22; for claim 114, see page 4, lines 29-30, page 6, lines 29-30; for claim 115, see page 5, lines 5-6, page 7, lines 11-16, page 16, lines 17-21; for claims 116 and 117, see page 7, lines 17-19, page 16, lines 21-26; for claims 118 and 119, see page 7, lines 20-23, page 16,

lines 27-29; for claims 120-122, see page 17, lines 3-10; for claim 123, see page 5, lines 21-24 and Example 11; for claims 124-125, see page 15, lines 3-6; for claim 126, see page 15, lines 9-11; for claim 127, see page 15, lines 28-31 and page 16, lines 1-3; for claims 128 and 129, see Example 15; for claim 130, see Example 14; for claim 131, see page 19, lines 9-18; for claim 132, see page 19, lines 26-31, page 20, lines 1-5; for claims 133 and 134, see Example 16.

The amendments to the specification update the priority data and incorporate the sequence listing into the specification.

CONCLUSION


Accordingly, the claims are now in condition for allowance and a notice to that effect is respectfully requested.

No fee is believed due for this preliminary amendment; however, if a fee is due, please charge Deposit Account No. 12-2475 for the appropriate amount.

Respectfully submitted,

LYON & LYON LLP

Dated: December 16, 1999

By: 
Charles S. Berkman
Reg. No. 38,077

633 West Fifth Street, Suite 4700
Los Angeles, California 90071-2066
(858) 552-8400